An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum

Archives of Pathology and Laboratory Medicine

Volumn 120, Issue 7, 1996, Pages 654-659

  Mosnier, Jean François ^a,b   Gentil Perret, Anne ^a   Vindimian, Monique ^a   Dumollard, Jean Marc ^a   Balique, Jean Gabriel ^a   Perpoint, Bruno ^a   Boucheron, Simonne ^a  

^a SERVICE DE NEUROLOGIE   (France)

^b Service d'Anatomie Pathologique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COLON ADENOMA; COLON CARCINOMA; COLON POLYP; COLON TUMOR; CONTROLLED STUDY; FEMALE; GENE CONTROL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RECTUM TUMOR; REGULATORY MECHANISM;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLON; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYPS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 8944236536     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Nowell PC. Mechanisms of tumor progression. Cancer Res. 1986;46:2203-2207.
2. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.
3. Fearon ER, Vogelstein A, A genetic model for colorectal tumorogenesis. Cell. 1990;61:759-767.
4. Hamilton ER. The molecular genetics of colorectal neoplasia. Gastroenterology. 1993;105:3-7.
5. Muleris M, Salmon RJ, Zafrani B, Girodet J, Dutrilleux B. Consistent deficiencies of chromosome 18 and the short arm of chromosome 17 in eleven cases of human large bowel cancer: a possible recessive determinism. Ann Genet. 1985;28:206-213.
6. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science. 1987;238:193-197.
7. Reichman A, Martin P, Levin B. Chromosomal banding patterns in human large bowel cancer. Int J Cancer. 1981;28:431-440.
8. Bonner MP, Culin C, Reed JC, Furth EE. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol. 1995;146:20-26.
9. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene. 1994;9:3367-3370.
10. Bosari S, Moneghini L, Graziani D, et al. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol. 1995;26: 534-540.
11. Baretton GB, Diebold J, Christoforis G, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas: aspects of carcinogenesis and prognostic significance. Cancer. 1996;77:255-264.
12. Hockenberry D, Nunez G, Milliman C, Screiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;137:225-232.
13. Korsmeyer SJ. BcS-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879-886.
14. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1993;124:1-6.
15. Nunez G, London L, Hockenberry D. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor deprived hemopoietic cell lines. J Immunol. 1990;144:3602-3610.
16. MacDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high grade malignant lymphoma in mice transgenic for the t(14;18). Nature. 1991;349:254-256.
17. Yonis-Rouach E, Resnitsky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin 6. Nature. 1991;352:345-347.
18. Shaw P, Bovey R, Tardy S, Sahali R, Soradt B, Costa J. Induction of apoptosis by wild type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA. 1992;89:4495-4499.
19. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847-849.
20. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocytes apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849-852.
21. Miyashita M, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799-1805.
22. Remvikos Y, Tominaga O, Hammel P, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer. 1992;66:758-764.
23. Hamelin R, Laurent-Puig L, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 1994;106:42-48.
24. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
25. Deans GT, Parks TG, Rowlands BJ, Spence RAJ. Prognostic factors in colorectal cancer. Br J Surg. 1992;79:608-613.
26. Crissman JD, Barwick KW. Pathologic staging of colon and rectal adenocarcinoma. In: Wanebo HJ, ed. Colorectal Cancer. St Louis, Mo: Mosby-Year-book; 1993:53-74.
27. Crissman JD, Zarko RJ, Ma CK, Visscher DW. Histopathologicparameters and DNA analysis in colorectal adenocarcinomas. Pathol Annu. 1989;24:103-147.
28. Halvorsen TB, Seim E. Degree of differentiation in colorectal adenocarcinomas: a multivariate analysis of the influence of survival. J Clin Pathol. 1988;41: 532-537.
29. American Joint Comittee on Cancer. Manual for Staging of Cancer. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1988.
30. Mason DY, Sammons RE. The labeled antigen method of immunoenzymatic staining. J Histochem Cytochem. 1979;27:832-840.
31. Graham RC, Karnovsky MJ. The early stages of absorption of horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem. 1966;14:291-302.
32. Buttyan R, Olsson CA, Pintar J, et al. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol. 1989;9:3473-3481.
33. Pezella T, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14:18 chromosomal translocation. Am J Pathol. 1990;137:225-232.
34. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol. 1993;143:390-400.
35. Hockenberry DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA. 1991;88:6961-6965.
36. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in foetal tissues suggests a role in morphogenesis. Am J Pathol. 1993;142:743-753.
37. Lu Q-L, Poulson R, Wong L, Hanby A. Bcl-2 expression in adult and embryonic non haematopoetic tissues. J Pathol. 1993;161:431-437.
38. Clark WH. Tumor progression and the nature of cancer. Br J Cancer. 1991;64:631.
39. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217-221.
40. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990;247:49-56.
41. Levine AJ, Momand J, Finlay CA. The tumour suppressor gene. Nature. 1991;351:453-455.
42. Hollstein M, Sidansky D, Vogelstein D, Harris CC. p53 mutations inhuman cancers. Science. 1991;253:49-53.
43. Oliner JD, Kinzler KW, Meltzer PS, Goeorge DL, Vogelstein B. Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature. 1992;358:80-83.
44. Bass IO, Mulder IWR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1992;172:5-12.
45. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited! J Pathol. 1994;172:1-4.
46. McKee PH, Hobbs C, Hall PA. Antigen microwave irradiation lowers immunohistochemical detection tresholds. Histopathology. 1995. In press.
47. Bertolle R, Esposito G, Del Mistro A, Belluco C, Nitti D, Chieco-Bianchi L. Association of p53 gene and protein alterations with metastasis in colorectal cancer. Am J Surg Pathol. 1995;19:463-471.
48. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 1993;8:3427-3331.
49. Jego N, Thomas G, Hamelin R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene. 1993;8:209-213.
50. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic correlation. Br J Cancer. 1991;63:317-319.
51. Kawasaki Y, Monden T, Morimoto H, et al. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol. 1992;97:244-249.
52. Campo E, Calle-Martin O, Miquel R, et al. Loss of heterozygosity of p53 gene expression in human colorectal carcinomas. Cancer Res. 1991;51:4436-4442.
53. Sun XF, Carstensen JM, Zhang H, et al. Prognosis significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 1992;340:1369-1373.
54. Starzynska T, Bromley M, Ghohsh A, Stern PL. Prognosis significance of p53 overexpression in gastric and colorectal cancer. Br J Cancer. 1992;66:558-562.